|
|
Article: Neurocrine Reports Indiplon Effective in Treating Elderly Patients With Difficulties Maintaining Sleep; Indiplon Modified Release Demonstrates Highly Statistically Significant Improvement in Sleep Maintenance.
- Article from:
- PR Newswire
- Article date:
- March 2, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences, Inc. today announced positive results from its Phase III trial with the modified release formulation of indiplon, achieving highly statistically significant results in elderly patients with chronic insomnia who have sleep maintenance difficulties. Results demonstrated that with indiplon 20 mg modified release, patients achieved rapid sleep onset and maintained sleep. The primary endpoint for the study was patient reported Total Sleep Time (sTST). Efficacy results with indiplon modified release demonstrated a highly statistically significant improvement in sTST (p
Secondary sleep maintenance endpoints including patient reported Total Wake Time ...